2 min readResearchers Capture First Images of Oxygen in Cancer Tumours during Radiation Therapy
Lebanon, NH — Oxygen in cancer tumours is known to be a major factor that helps radiation therapy be successful. Hypoxia, or starvation of oxygen, in solid tumors is also thought to be an important factor in resistance to therapy. However, it is difficult to monitor tumour oxygenation without invasive sampling of oxygen distributions throughout the tissue, or without averaging across the whole tumour, whereas oxygen is highly heterogenous within a tumour. A research team at Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center led by Dr. Brian Pogue, has developed the first non-invasive way to directly monitor oxygen distributions within the tumour right at the time when radiation therapy is happening. With injection of an oxygen probe drug, PtG4, they are able to image the distribution of oxygen from within the tumour. The method measures the luminescence lifetimes of PtG4 while it is excited by the Cherenkov light emitted by the radiation therapy. The drug, PtG4, stays in the tumour for at least a week, and works for imaging repeatedly.
“The imaging is all done without any additional radiation, simply by using a camera to monitor the emissions during radiotherapy treatment,” explains Pogue. “Following two tumour lines, one which is known to be responsive to radiation and one which is known to be resistant, we could see differences in the oxygenation of the tumour which are reflective of their differences in response.” The team’s findings, “Tissue pO2 Distributions in Xenograft Tumors Dynamically Imaged by Cherenkov-Excited Phosphorescence during Fractionated Radiation Therapy,” are newly published in Nature Communications, by lead author, Xu Cao.
Pogue’s team is able to capture oxygenation imaging through special technology. “We have a unique set of time-gated cameras in our radiation therapy department that were designed for Cherenkov-based radiation dosimetry, but we have used them for this additional purpose of monitoring oxygen in the tumours under treatment,” says Pogue. “So access to these specialized Cherenkov cameras made the measurements possible.” Pogue’s team also collaborated with Professor Sergei Vinogradov and his team at the University of Pennsylvania Perelman School of Medicine, who produced the PtG4 and supported the work with drug characterization and co-supervision of the study.
Pogue hopes to develop this tumour monitoring ability into a useful clinical aid used to track tumour response to radiation therapy, especially tumours that are known to be hypoxic. Having such information available at the time of treatment could be helpful in influencing treatment decisions such as giving a radiation boost where needed. “When a patient gets radiation therapy, the treatment should be designed to directly utilize as much information about the patient’s tumour as possible,” says Pogue. “Today, we use the shape of the tumour and the tissue around it. But, we need to also think about using measurements of the tumour metabolism because this affects the success of treatment as well. Future radiation therapy treatments should ideally incorporate metabolic features such as oxygenation of the tumour when the treatment is planned or delivered.”
The next steps toward this future are already underway. Pogue’s team is looking to characterize how small of a region they can track the oxygenation from, and how fast they can take measurements. “Our goal is to produce oxygen images at video rate, with a spatial resolution that allows us to see radiobiologically relevant hypoxia nodules in the tumor of humans,” explains Pogue.
Article adapted from a Dartmouth-Hitchcock Medical Center news release.
Publication: Tissue pO2 distributions in xenograft tumors dynamically imaged by Cherenkov-excited phosphorescence during fractionated radiation therapy. Cao, X et al. Nature Communications (January 29, 2020): Click here to view.